Back to search results

Ivonescimab for Recurrent Glioblastoma

This study is testing a drug called ivonescimab for people with recurrent glioblastoma, a type of brain cancer. Ivonescimab is given through an infusion (IV). The first part of the study aims to find the safest and most effective dose of ivonescimab. The second part will then see if this dose can help control the disease. You might be able to join if you are at least 18 years old, have recurrent glioblastoma that has progressed after standard treatments, and have a Karnofsky Performance Status (KPS) of 60 or higher, meaning you can mostly care for yourself. The study will look at how safe ivonescimab is and how well it prevents the cancer from growing.

Study design
This is a Phase I/II interventional study with a planned enrollment of 45 participants. It aims to first find the right dose and then evaluate its effectiveness.
What's involved
You will receive ivonescimab through an infusion by vein. The study will monitor your safety and any side effects through study completion, which is an average of 1 year.
Compensation
Not stated in the trial record.
Follow-up
Your safety and adverse events will be measured through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06672575

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~45 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Ivonescimab

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Glioblastoma

Explore related trials

GlioblastomaIDH1 wt Allele

Where it's being run

2 sites across 1 states
Texas2

Study leadership

  • Anuj D Patel, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Evguenia Gachimova, MD
[email protected]
832-266-3519
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

1.5 × ULN, and partial prothrombin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless abnormalities are unrelated to coagulopathy or prophylactic coagulation) 8. Female patients of childbearing age must have negative serum pregnancy test results before randomization or per region-specific guidance documented in the informed consent and a negative urine pregnancy test on the day of first dose prior to dosing. 9. Female patient of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 90 days after the last dose of the ivonescimab. 10. Male patients of childbearing potential having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until Day 90 after the last dose of ivonescimab. 11. Ability to understand and willingness to sign informed consent form prior to the initiation of study and any study procedures.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0